These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 9290695)

  • 1. Update on active specific immunotherapy with melanoma vaccines.
    Conforti AM; Ollila DW; Kelley MC; Gammon G; Morton DL
    J Surg Oncol; 1997 Sep; 66(1):55-64. PubMed ID: 9290695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.
    Ollila DW; Kelley MC; Gammon G; Morton DL
    Semin Surg Oncol; 1998 Jun; 14(4):328-36. PubMed ID: 9588726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of response to anticancer immunotherapy using gene signatures.
    Wang E; Bedognetti D; Marincola FM
    J Clin Oncol; 2013 Jul; 31(19):2369-71. PubMed ID: 23715576
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
    Morton DL
    Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma vaccines.
    Minev BR
    Semin Oncol; 2002 Oct; 29(5):479-93. PubMed ID: 12407513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines.
    Ralph SJ
    Am J Clin Dermatol; 2007; 8(3):123-41. PubMed ID: 17492842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
    Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
    Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
    Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
    J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
    Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
    J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
    Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
    J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
    Sosman JA; Sondak VK
    Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
    Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C
    J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor vaccines: a role in preventing recurrence in melanoma?
    Sabel MS; Sondak VK
    Am J Clin Dermatol; 2002; 3(9):609-16. PubMed ID: 12444803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer vaccines with emphasis on a viral oncolysate melanoma vaccine.
    Horvath JC; Horak A; Sinkovics JG; Pritchard M; Pendleton S; Horvath E
    Acta Microbiol Immunol Hung; 1999; 46(1):1-20. PubMed ID: 10331063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma vaccines.
    Perales MA; Wolchok JD
    Cancer Invest; 2002; 20(7-8):1012-26. PubMed ID: 12449735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical activity of a polyvalent melanoma antigen vaccine.
    Bystryn JC
    Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
    Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
    Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel immunologic approaches to the management of malignant melanoma.
    Weber JS; Aparicio A
    Curr Opin Oncol; 2001 Mar; 13(2):124-8. PubMed ID: 11224710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active immunotherapy with allogeneic tumor cell vaccines: present status.
    Chan AD; Morton DL
    Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.